RESUMO
PSA and PSAP were examined in 198 prostatic biopsies and correlated with PSA and PSAP serum levels evaluated before biopsies. In every type of lesion there was no relation between PSA or PSAP serum levels and their expression in biopsy specimens. PSA and PSAP staining was similar in both cancer and benign hyperplasia and lower in dysplasia, atrophy and prostatitis; while serum levels were higher in adenocarcinomas than in other lesions. A significant difference of PSAP serum levels was noted in different Gleason's grading of neoplasia, found neither with PSA serum levels/nor with PSA and PSAP tissue staining.
Assuntos
Fosfatase Ácida/análise , Adenocarcinoma/patologia , Antígeno Prostático Específico/análise , Próstata/patologia , Hiperplasia Prostática/patologia , Neoplasias da Próstata/sangue , Neoplasias da Próstata/patologia , Fosfatase Ácida/sangue , Adenocarcinoma/sangue , Atrofia , Biópsia por Agulha , Humanos , Imuno-Histoquímica , Masculino , Antígeno Prostático Específico/sangue , Hiperplasia Prostática/sangueRESUMO
At the moment, proton-therapy is the most advanced radiotherapeutic technique in cancer treatment. The use of the high energy proton beam (from 70 MeV to 200 MeV) lets a Bragg's peak be moved to different depths, so allowing personal radiotherapeutic treatment. In recent years, many proton-therapy centers have grown up throughout the world with very satisfactory clinical results, first of all in eye melanoma treatment. The future expectations are very promising, even if the very high installation and maintenance expenses of a synchrotron (for proton production) hinder the development of such a method.
